

*Original Research***Antibiotic Resistance Profiling of *Campylobacter jejuni* Isolated from Poultry in India****Rahul Yadav<sup>1\*</sup> and Sunil Maherchandani<sup>2</sup>**<sup>1</sup>Ph. D. Scholar, Department of Veterinary Microbiology and Biotechnology, College of Veterinary and Animal Science, RAJUVAS, Bikaner, Rajasthan, INDIA<sup>2</sup>Professor, Department of Veterinary Microbiology and Biotechnology, College of Veterinary and Animal Sciences, RAJUVAS, Bikaner, Rajasthan, INDIA**\*Corresponding author:** [drrahul16889@gmail.com](mailto:drrahul16889@gmail.com)

<b>Rec. Date:</b>	Jan 16, 2020 05:14
<b>Accept Date:</b>	Feb 22, 2020 06:46
<b>DOI</b>	<a href="https://doi.org/10.5455/ijlr.20200116051419">10.5455/ijlr.20200116051419</a>

**Abstract**

The present study was conducted for detection of antibiotic resistance in *Campylobacter jejuni* isolates of poultry origin in India. Highest (100%) antibiotic sensitivity was observed for chloramphenicol and aminoglycosides (gentamicin, amikacin) whereas high antibiotic resistance was observed against  $\beta$ -lactam antibiotics and fluoroquinolone antibiotics (ciprofloxacin, ofloxacin, nalidixic acid and norfloxacin) in in vitro antibiotic susceptibility testing and MIC determination as well. The *gyrB* gene which codes for proteins responsible for fluoroquinolone resistance was detected in 100% of the isolates followed by *gyrA* gene (95.34%). The *gyrA* gene-based phylogeny represented close homology of our *C. jejuni* isolates with isolates from Europe and didn't represent homology with isolates from India in public domain.

**Key words:** Antibiotic Resistance, *Campylobacter jejuni*, Poultry**How to cite:** Yadav, R., & Maherchandani, S. (2020). Antibiotic Resistance Profiling of *Campylobacter jejuni* Isolated from Poultry in India. International Journal of Livestock Research, 10(3), 141-151. doi: 10.5455/ijlr.20200116051419**Introduction**

*Campylobacter jejuni* is considered as most emerging food borne zoonotic pathogen and had received serious attention due to high fluoroquinolones and macrolide resistance in many parts of the world (Epps *et al.*, 2013). Poultry are the major reservoir of this bacterium and responsible for transmission of infection through poultry products. Supplementation of antibiotics in poultry feed have evolved bacterial strains to be multidrug resistant (Mani *et al.*, 2018). *Campylobacter* species are intrinsically resistant to a number of antibiotics, including cefoperazone, cephalothin, bacitracin, vancomycin, rifampin and trimethoprim (Acheson and Allos, 2001), some of these are utilized in selective media for isolation. Resistance may be chromosomal or plasmid-borne, and represent a combination of endogenous and acquired genes *viz.*

modification of the antibiotic's target and/or its expression (DNA gyrase mutations), inability of the antibiotic to reach its target (expression of the major outer membrane protein or MOMP), efflux of the antibiotic (multidrug efflux pumps such as *cmeABC*), modification or inactivation of the antibiotic ( $\beta$ -lactamase production) (Iovine, 2013).

In last few decades, intensive rearing of poultry along with indiscriminate use of antibiotics such as fluoroquinolone as feed additives, growth enhancer and therapeutics has resulted in emergence of multiple antibiotic resistant *Campylobacter* strains in habitat (Wieczorek and Osek, 2013). The resistant bacteria can be transmitted through contaminated poultry meat and eggs into humans (El-baky *et al.*, 2014). World health organization has given advisory for limiting the use of fluoroquinolones in poultry sector as therapeutic and feed supplement in most of the western countries a decade ago. US Food and Drug Administration also have withdrawn use of fluoroquinolone from poultry since 2005 (Nelson *et al.*, 2007). Monitoring drug resistance pattern among the *Campylobacter* isolates not only gives vital clues to the clinician regarding the judicious therapeutic regime to be adopted against individual cases, but also an important tool to devise a comprehensive chemoprophylactic and chemotherapeutic drug schedule within a geographical area among human and animal origin isolates (Siddiqui *et al.*, 2015).

Antibiotic resistance patterns may vary on source of infection and geographical area. There is only few reports published from Indian origin isolates regarding antibiotic resistance of *C. jejuni* isolates in public domain (Chatur *et al.*, 2014). Therefore, present study was carried out for detection of antibiotic resistance profile of *C. jejuni* isolates from poultry origin in India.

## Material and Methods

### Determination of *In vitro* Antibiotic Susceptibility Test with MIC

A number of 43 *C. jejuni* were isolated from local poultry farms in and around Bikaner, Rajasthan, India (Yadav *et al.*, 2016). Antibiotic sensitivity testing was done against 24 antibiotics belonging to different class, generation and mechanism of action as per the method described by Bauer *et al.* (1966) following the guidelines of Clinical laboratory standard institute (Wayne, 2010; 2011) and European committee on antimicrobial susceptibility (Kahlmeter, 2006). Due to poor visibility of zone of inhibition on M-H plates; for the present study 0.5 McFarland concentrations of *Campylobacter* enrichment broth culture (*Preston* enrichment broth base, Himedia) supplemented with *Campylobacter* supplement IV (Himedia) and 7% lysed horse blood was then swabbed on modified charcoal cefoperazone deoxycholate agar (mCCDA) plate including *Campylobacter* supplement V (Himedia) with the help of sterile cotton swab. On this medium the visibility of zones of inhibition was clearer. Variations in standard disk diffusion method have been approved by Wayne (2010) for *Campylobacter* isolates (Beek *et al.*, 2010). MIC determination was done by Ezy MIC™ strips of six antibiotics (amikacin, erythromycin, chloramphenicol, gentamicin,

ciprofloxacin and ofloxacin) with similar procedure as described above. Zone of inhibition for an antibiotic were interpreted as per the standards of *Enterobacteriaceae* (Shin *et al.*, 2015) defined by clinical laboratory standards institute (Wayne, 2011). All Multidrug resistant isolates were evaluated for their multiple antibiotics resistance (MAR) index (Krumperman, 1983).

### Amplification of Virulence Associated Genes

Molecular detection of various antibiotic resistance genes *i.e.* tetracycline, aminoglycosides, multidrug resistance efflux and integrons were done using earlier reported primer sets and/or primer set designed for the present study (Table 1). The primers were designed by primer 3 tool of NCBI for *cmrABC* (multidrug efflux pump) and *aph3* (aminoglycosides resistance) gene in this study. All PCR amplifications were performed in a mixture (25  $\mu$ l) containing: 2.5 $\mu$ l of the 10X PCR buffer, 2.5 $\mu$ l of MgCl<sub>2</sub> (25 mM), 0.5  $\mu$ l of dNTPs (10 mM), 1  $\mu$ l of each primer (100  $\mu$ M), 0.5  $\mu$ l (1U) of the *Taq* DNA polymerase (Promega), 3  $\mu$ l of the bacterial template DNA and 14  $\mu$ l nuclease free water. The PCR products were analyzed by electrophoresis on 1.5% agarose gel for 1 h at 100V. The gel was then visualized under UVP gel documentation system (BioDoc-It Imaging System).

### Sequence Analysis of *gyrA* Gene

PCR products of partial *gyrA* gene partial cds from nine representative of *C. jejuni* isolates were sequenced (DNA Sequencing Facility, Delhi University). The sequences obtained were subjected to NCBI nucleotide Basic Local Alignment Search tool (BLAST) to determine the similarity with the already prevalent gene sequences. The nucleotide sequences (accession number KY084915 to KY084923) were submitted to NCBI genebank. The sequences were also aligned using Bio edit and MEGA6 software to study the variations in the nucleotide sequences and their phylogenetic cluster analysis (Bikandi *et al.*, 2004).

**Table 1:** PCR primers and conditions for detection of antibiotic resistance genes

S. no	Antibiotic resistance gene	Gene name	Primer sequence	A. temp (°C)	Size (bp)	Reference
<b>Antibiotic Resistance genes</b>						
1	<b>Tetracycline resistance genes</b>	<i>tetO</i>	F-AACTTAGGCATTCTGGCTCAC	56	515	Abdi-Hachesooet al. (2014)
			R-TCCCACTGTTCCATATCGTCA			
2		<i>tetA</i>	F-GTAATTCTGAGCACTGTGCGC	57	956	
			R-CTGCCTGGACAACATTGCTT			
3		<i>tetB</i>	F-CTCAGTATTCCAAGCCTTTG	52	414	
			R-ACTCCCCTGAGCTTGAGGGG			
4		<i>tetC</i>	F-GGTTGAAGGCTCTCAAGGGC	62	505	
	R-CCTCTTGCGGGATATCGTCC					
5	<i>tetD</i>	F-CATCCATCCGGAAGTGATAGC	57	485		
		R-GGATATCTCACCGCATCTGC				
6	<i>tetE</i>	F-TGATGATGGCACTGGTCA	57	262		
		R-GCTGGCTGTTGCCATTA				
7	<i>tetG</i>	F-GCAGCGAAAGCGTATTTGCG	62	662		
		R-TCCGAAAGCTGTCCAAGCAT				
<b>Multidrug resistance determinants genes</b>						
8	<b>Aminoglycoside resistance genes</b>	<i>aph3</i>	F-TTCTAGCCACGACCAAAAAG	56	363	Current study
			R-CGTGAGCCATAAAGTCTAGC			
9		<i>strA</i>	F-CCAATCGCAGATAGAAGGC	55	286	
	R-CTTGGTGATAACGGCAATTC					
10	<i>aadA2</i>	F-ATTTGCTGGTTACGGTGACC	59	451	Scholz_et al. (1989)	
		R-CTTCAAGTATGACGGGCTGA				
11	<b>Fluoroquinolone resistance genes</b>	<i>gyrA</i>	F-GAAGAATTTTATATGCTATG	50	235	Chatur_et al. (2014)
			R-TCAGTATAACGCATCGCAGC			
12		<i>gyrB</i>	F-ATGGCAGCTAGAGGAAGAGA	53	382	
	R-GTGATCCATCAACATCCGCA					
13	<i>parC</i>	F-CTATGCGATGTCAGAGCTGG	59	285		
		R-TAACAGCAGCTCGGCGTATT				
14	<b>Efflux pump (<i>cmeABC</i> operon) genes</b>	<i>cmeRABC</i> , Strain	F-CAATCTTCAATCAGGGGCAA	56	625	Current study
			R-TCGCAAAAAGAGTGCACATA			
15	<b>Integron genes</b>	<i>int1F</i>	F-CCTCCCGCACGATGATC	55	280	Moura_et al. (2007)
		<i>int1R`</i>	R-TCCACGCATCGTCAGGC			
16		<i>int2F</i>	F-TTATTGCTGGGATTAGGC	50	233	
			<i>int2R</i>			
17		<i>int3F</i>	F-AGTGGGTGGCGAATGAGTG	50	600	
	<i>int3R</i>		R-TGTTCTTGATCGGCAGGTG			

## Results and Discussion

### Determination of *In vitro* Antibiotic Susceptibility Test with MIC

All the 43 isolates were subjected to antibiotic sensitivity testing against 24 antibiotics of different classes and generation. Highest (100%) sensitivity was observed for polymyxin-B followed by chloramphenicol (97.67%), gentamicin (95.35%), amikacin (88.37%), aztreonam (83.72%), meropenem and imipenem (76.74%), kanamycin (72.09%), ceftriaxone (65.12%), erythromycin and ampicillin (53.49%). Isolates were 100% resistant to Penicillin-G, methicillin and rifampicin. Relatively lower level of resistance was detected against cephalothin (95.35%), vancomycin (93.02%), ciprofloxacin (90.70%), ofloxacin (79.07%), nalidixic acid (74.42%) and norfloxacin (72.09%). High resistance was observed against  $\beta$ -lactam antibiotics. Similarly, a very high resistance (100%) against fluoroquinolone group of antibiotics (ciprofloxacin, ofloxacin, nalidixic acid and norfloxacin) was also seen.

In the present investigation, all 43 isolates were subjected to MIC determination for six antibiotics *i.e.* erythromycin (2 to 12 mcg/ml), gentamicin (0.38 to 6 mcg/ml), chloramphenicol (3 to 16 mcg/ml), amikacin (0.5 to 32 mcg/ml) by Ezy MIC™ Strip method. Erythromycin has highest average MIC value of 5.74 mcg/ml followed by chloramphenicol (4.80 mcg/ml), amikacin (0.86 mcg/ml) and gentamicin (0.23 mcg/ml). None of the isolate formed any zone of inhibition for ciprofloxacin and ofloxacin, considered them to be 100% resistant. On the basis of their average MIC value, isolates were detected as sensitive for amikacin and gentamicin, intermediate for erythromycin and chloramphenicol and resistant for ciprofloxacin and ofloxacin.

Resistance against multiple antibiotics was observed by multiple antibiotic resistances (MAR) index which is an epidemiological tool used to assess the risk analysis of environment for bacterial contamination and acquisition of drug resistance through use of multiple antibiotics. If MAR index is greater than 0.2; it implies that strains of such bacteria originated from an environment where several antibiotics have been used (Krumperman, 1983). The average MAR index of the 43 isolates under study was 0.45 demonstrates high prevalence of multiple antibiotic resistant *C. jejuni* isolates from India (Table 2).


**Table 2:** Detection of multiple antibiotic resistance (MAR) index value among isolates

MAR Index Value Type (MAR)	Isolate I.D.	No. of Isolate	No. of antibiotic, which the isolate was resistant	Total no of antibiotics	MAR Index Value	Significance
MAR 1	C1, C18, C29, C30	4	7	24	0.29	43 (100%) isolates had 0.2 or more than 0.2 MAR index value with high risk potential source of spread MDR
MAR 2	C25, C28	2	8	24	0.33	
MAR 3	C7, C12, C14, C16, C22, C23, C26, C31, C42	9	9	24	0.38	
MAR 4	C24, C27, C36, C39, C40, C41	6	10	24	0.42	
MAR 5	C4, C5, C21, C37, C43	5	11	24	0.46	
MAR 6	C2, C3, C8, C13, C17, C20, C32, C34	8	12	24	0.5	
MAR 7	C6, C9, C11, C19, C38	5	13	24	0.54	
MAR 8	C35	1	14	24	0.58	
MAR 9	C10, C15, C33	3	15	24	0.63	
<b>TOTAL</b>		<b>43</b>			<b>19.17</b>	
<b>Average MAR Value</b>					<b>0.45</b>	

In agreement to our observation, Ghimire *et al.* (2014) detected 77.8% of the isolates with MAR index value >0.2. Multiple mechanisms associated with antibiotic resistance have been identified in *Campylobacter*, but target mutations and drug efflux are most relevant to the resistance to fluoroquinolones and macrolides (Luangtongkum *et al.*, 2009).

### Amplification of Virulence Associated Genes

PCR assay successfully amplify only seven genes (*tetO*, *aph3*, *gyrA*, *gyrB*, *cmeRABC*, *int1* and *int2*) out of 17 genes (Fig. 1). The *gyrB* gene which codes for proteins responsible for fluoroquinolone resistance was detected in 100% of the isolates followed by *gyrA* gene (95.34%), *tetO* and *aph3* genes (74.41%) and *cmeRABC* (72.09%) isolates. Out of three integron genes only *int1* (30.23%) and *int2* (6.97%) were amplified.




**Fig. 1:** Agarose gel electrophoresis image of various antibiotic resistance genes of *C. jejuni*

*Campylobacter* multidrug efflux pump (*cmeABC*) genes are major player in the efflux of bile acids and plays a critical role in facilitating *Campylobacter* colonization of the intestinal tract (Lin *et al.*, 2003; Elhadidy *et al.*, 2018). The isolates from present study harbored the *cmeABC* genes responsible for multidrug resistance. Integrons are not common in *Campylobacter* and do not considered to play a major role in the horizontal transfer of antibiotic resistance in *Campylobacter*. However, studies by Lee *et al.* (2002); O'Halloran *et al.* (2004) suggested the integrons-associated antibiotic resistance (aminoglycoside resistance genes (*aadA2* and *aacA4*), in *C. jejuni* and *C. coli*. Usually resistance towards tetracycline antibiotic occurs due to expression of various *tet* genes types *i.e tetA, tetB, tetC, tetE, tetg, tetO* found in plasmid as well as chromosome of various Gram positive and Gram-negative organism. However, only *tetO* was reported as highly prevalent in *Campylobacter* species (Dasti *et al.*, 2007). We also didn't detect any of the tetracycline genes except *tetO* in present study.

### Sequence Analysis of *gyrA* Gene

In addition, we also performed *gyrA* gene sequence based phylogenetic analysis. In addition to nine isolates from the current study, we selected 27 sequences (from across the world) of *gyrA* gene from the public domain. The phylogenetic analysis revealed three major clusters (Fig. 2). Five isolates from the present study grouped along with poultry and human isolates from Europe (Austria, Slovenia, Germany, Serbia, Bosnia and Herzegovina), New Zealand and Japan. Rest four isolates (C22, C25, C31, and C32) were grouped under separate cluster (cluster II) that has majority of isolates form USA. The previously reported *gyrA* gene sequences from India were grouped in separate cluster (Cluster III) and didn't represent close homology with the isolates from this study. Taken together *gyrA* gene-based phylogeny represented close homology of our *C. jejuni* isolates with isolates from Europe.



**Fig. 2:** Phylogenetic analysis of *gyrA* gene sequences

In this study, multidrug resistance was observed in more than 70% of the isolates and absolute resistance was determined for fluoroquinolones antibiotics by in vitro susceptibility testing, MIC determination, and detection of fluoroquinolones resistance genes i.e. *gyrA* and *gyrB*. While most microorganisms possess 2 fluoroquinolone-targets (DNA-Gyrase and Topoisomerase IV), *Campylobacter* spp. only possesses one of the DNA-Gyrases (Luangtongkum *et al.*, 2009). Resistance to fluoroquinolone is believed to develop more rapidly in *Campylobacter* spp, than in other Gram-negative bacteria, mainly attributed to single-step point mutation in Thr-86-Ile of *gyrA* gene (Luangtongkum *et al.*, 2009; Otigbu *et al.*, 2018). *gyrA* gene-based phylogenetic analysis of present study isolates showed close homology with isolates from Europe, rather

than isolates from India. High fluoroquinolones resistance has been reported by Chatur *et al.* (2014) in India previously. The reason for the high prevalence of fluoroquinolone resistance in India is unknown, but it might be driven by the use of fluoroquinolone in animal and poultry production (Collado *et al.*, 2018). In this increasing trend of fluoroquinolone resistance in our and previous studies indicate the need of interventions to limit spread of resistant isolates.

### Conclusion

Conclusively, *C. jejuni* isolates from present study are detected as multidrug resistant strains. High MAR values and MDR status of all the isolates is an indication of excessive use of antibiotics and is a point of concern. The antibiotic resistance patterns indicate that *C. jejuni* isolates have evolved themselves for resistance to fluoroquinolone group of antibiotics. The absolute fluoroquinolone resistance may acquire by cumulative effect of *gyrA* gene point mutation, efflux pump regulator *CmeRABC* gene and integrons. Such mutant strains are more stable as compared to fluoroquinolone sensitive strains and didn't carry fitness burden.

### Acknowledgment

The study was funded by Rajasthan University of Veterinary and Animal Sciences University (RAJUVAS), Bikaner as part of Ph. D dissertation of the first author Dr. Rahul Yadav under supervision of major advisor Prof. Sunil Maherchandani.

### Conflict of Interest

Authors don't have any conflict of interest.

### References

1. Abdi-hachesoo, B., Khoshbakht, R., Sharifiyazdi, H., Tabatabaei, M., Hosseinzadeh, S., & Asasi, K. (2014). Tetracycline resistance genes in *Campylobacter jejuni* and *C. coli* isolated from poultry carcasses. *Journal of Microbiology*, 7(9), e12129.
2. Acheson, D., & Allos, B. M. (2001). *Campylobacter jejuni* infections: update on emerging issues and trends. *Clinical infectious diseases*, 32(8), 1201-1206.
3. Bauer, A. W., Kirby, W. M. M., Sherris, J. C., & Turck, M. (1966). Antibiotic susceptibility testing by a standardized single disk method. *American Journal of Clinical Pathology*, 45(4), 493-496.
4. Beek, M. T., Claas, E. C. J., Mevius, D. J., Van Pelt, W., Wagenaar, J. A., & Kuijper, E. J. (2010). Inaccuracy of routine susceptibility tests for detection of erythromycin resistance of *Campylobacter jejuni* and *Campylobacter coli*. *Clinical Microbiology and Infection*, 16(1), 51-56.
5. Bikandi, J., Millán, R. S., Rementeria, A., & Garaizar, J. (2004). In silico analysis of complete bacterial genomes, PCR, AFLP-PCR and endonuclease restriction. *Bioinformatics*, 20(5), 798-799.
6. Chatur, Y. A., Brahmabhatt, M. N., Modi, S., & Nayak, J. B. (2014). Fluoroquinolone resistance and detection of topoisomerase gene mutation in *Campylobacter jejuni* isolated from animal and human sources. *International Journal of Current Microbiology and Applied Science*, 3(6), 773-783.
7. Collado, L., Muñoz, N., Porte, L., Ochoa, S., Varela, C., & Muñoz, I. (2018). Genetic diversity and clonal characteristics of ciprofloxacin-resistant *Campylobacter jejuni* isolated from Chilean patients with gastroenteritis. *Infection, Genetics and Evolution*, 58, 290-293.

8. Dasti, J. I., Groß, U., Pohl, S., Lugert, R., Weig, M., & Schmidt-Ott, R. (2007). Role of the plasmid-encoded tet (O) gene in tetracycline-resistant clinical isolates of *Campylobacter jejuni* and *Campylobacter coli*. *Journal of medical microbiology*, 56(6), 833-837.
9. El-Baky, R. A., Sakhy, M., & Gad, G. F. M. (2014). Antibiotic susceptibility pattern and genotyping of campylobacter species isolated from children suffering from gastroenteritis. *Indian journal of medical microbiology*, 32(3), 240.
10. Elhadidy, M., Miller, W. G., Arguello, H., Álvarez-Ordóñez, A., Duarte, A., Dierick, K., & Botteldoorn, N. (2018). Genetic basis and clonal population structure of antibiotic resistance in *Campylobacter jejuni* isolated from broiler carcasses in Belgium. *Frontiers in microbiology*, 9, 1014.
11. Epps, S., Harvey, R., Hume, M., Phillips, T., Anderson, R., & Nisbet, D. (2013). Foodborne *Campylobacter*, infections, metabolism, pathogenesis and reservoirs. *International Journal of Environmental Research and Public Health*, 10(12), 6292-6304.
12. Ertaş, H. B., Çetinkaya, B., Muz, A., & Öngör, H. (2004). Genotyping of broiler-originated *Campylobacter jejuni* and *Campylobacter coli* isolates using fla typing and random amplified polymorphic DNA methods. *International Journal of Food Microbiology*, 94(2), 203-209.
13. Ghimire, L., Singh, D. K., Basnet, H. B., Bhattarai, R. K., Dhakal, S., & Sharma, B. (2014). Prevalence, antibiogram and risk factors of thermophilic *Campylobacter* spp. in dressed porcine carcass of Chitwan, Nepal. *BMC microbiology*, 14(1), 85.
14. Iovine, N. M. (2013). Resistance mechanisms in *Campylobacter jejuni*. *Virulence*, 4(3), 230-240.
15. Kahlmeter, G., Brown, D.F.J., Goldstein, F.W., MacGowan, A.P., Mouton, J.W., Odenholt, I., Rodloff, A., Soussy, C.J., Steinbakk, M., Soriano, F. & Stetsiouk, O. (2006). European Committee on Antimicrobial Susceptibility Testing (EUCAST) technical notes on antimicrobial susceptibility testing. *Clinical Microbiology and Infection*, 12(6), 501-503.
16. Krumperman, P. H. (1983). Multiple antibiotic resistance indexing of *Escherichia coli* to identify high-risk sources of fecal contamination of foods. *Applied Environmental Microbiology*, 46(1), 165-170.
17. Lee, M. D., Sanchez, S., Zimmer, M., Idris, U., Berrang, M. E., & McDermott, P. F. (2002). Class 1 integron-associated tobramycin-gentamicin resistance in *Campylobacter jejuni* isolated from the broiler chicken house environment. *Antimicrobial agents and chemotherapy*, 46(11), 3660-3664.
18. Lin, J., Sahin, O., Michel, L. O., & Zhang, Q. (2003). Critical role of multidrug efflux pump CmeABC in bile resistance and in vivo colonization of *Campylobacter jejuni*. *Infection and immunity*, 71(8), 4250-4259.
19. Luangtongkum, T., Jeon, B., Han, J., Plummer, P., Logue, C. M., & Zhang, Q. (2009). Antibiotic resistance in *Campylobacter*, emergence, transmission and persistence. *Future Microbiology*, 4(2), 189-200.
20. Mani, M., Pandey, R., Rautela, R. & Trivedi, R. (2018). Epidemiological Studies on Animals and Humans as Reservoirs of Thermophilic *Campylobacters*. *International Journal of Livestock Research*, 8(6), 203-211.
21. Moura, A., Henriques, I., Ribeiro, R., & Correia, A. (2007). Prevalence and characterization of integrons from bacteria isolated from a slaughterhouse wastewater treatment plant. *Journal of Antimicrobial Chemotherapy*, 60(6), 1243-1250.
22. Nelson, J. M., Chiller, T. M., Powers, J. H., & Angulo, F. J. (2007). Fluoroquinolone-resistant *Campylobacter* species and the withdrawal of fluoroquinolones from use in poultry, a public health success story. *Clinical Infectious Diseases*, 44(7), 977-980.
23. O'Halloran, F., Lucey, B., Cryan, B., Buckley, T., & Fanning, S. (2004). Molecular characterization of class 1 integrons from Irish thermophilic *Campylobacter* spp. *Journal of Antimicrobial Chemotherapy*, 53(6), 952-957.
24. Otigbu, A., Clarke, A., Fri, J., Akanbi, E., & Njom, H. (2018). Antibiotic sensitivity profiling and virulence potential of *Campylobacter jejuni* isolates from estuarine water in the Eastern Cape Province, South Africa. *International Journal of Environmental Research and Public Health*, 15(5), 925.

25. Scholz, P., Haring, V., Wittmann-Liebold, B., Ashman, K., Bagdasarian, M., & Scherzinger, E. (1989). Complete nucleotide sequence and gene organization of the broad-host-range plasmid RSF1010. *Gene*, 75(2): 271-288.
26. Shin, E., Hong, H., Oh, Y., & Lee, Y. (2015). First report and molecular characterization of a *Campylobacter jejuni* isolate with extensive drug resistance from a travel-associated human case. *Antimicrobial Agents and Chemotherapy*, 59(10), 6670-6672.
27. Siddiqui, F. M., Akram, M., Noreen, N., Noreen, Z., & Bokhari, H. (2015). Antibiotic susceptibility profiling and virulence potential of *Campylobacter jejuni* isolates from different sources in Pakistan. *Asian Pacific journal of tropical medicine*, 8(3), 197-202.
28. Wayne, P. A. (2010). Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria, approved guideline—. *Document M45-A2*.
29. Wayne, P. A. (2011). Performance standards for antimicrobial susceptibility testing; Twenty-first Informational Supplement. *CLSI Document M100-S21, Clinical and Laboratory Standards Institute*.
30. Wiczorek, K., & Osek, J. (2013). Antimicrobial resistance mechanisms among *Campylobacter*. *BioMed Research International*, 2013.
31. Wilkerson, C., Samadpour, M., van Kirk, N., & Roberts, M. C. (2004). Antibiotic resistance and distribution of tetracycline resistance genes in *Escherichia coli* O157: H7 isolates from humans and bovines. *Antimicrobial Agents and Chemotherapy*, 48(3): 1066-1067.
32. Yadav, R., Gahlot, K., Yadav, J., Purva, M., Bhati, T., Deora, A., Kumar, P., Maherchandani, S., & Kashyap, S.K. (2016). Prevalence of thermophilic *Campylobacter jejuni* isolated from cloacal samples of poultry. *Haryana Veterinary Journal*. 55(2): 195-197.